对2例老年急性髓系白血病患者口服伏立康唑的药学监护  

Pharmaceutical Care of Voriconazole Oral Administration of Two Cases of Elder Patients of Acute Myelogenous Leukemia

作　　者：贾立华 李忠东[2] Jia Lihua;Li Zhongdong(Department of Pharmacy,Beijing Beiya Orthopedics Hospital,Beijing 102445,China;Department of Pharmacy,Beijing Electric Power Hospital,State Electric Grid Co.)

机构地区：[1]北京北亚骨科医院药学部,北京102445 [2]北京电力医院药剂科

出　　处：《药物流行病学杂志》2019年第8期543-546,共4页Chinese Journal of Pharmacoepidemiology

基　　金：十二五科技支撑子课题-安全合理用药评价和干预技术研究与应用项目(编号:2013BAI06B04)

摘　　要：本文探讨了临床药师利用血药浓度监测和基因检测手段,对2例老年急性髓系白血病患者开展口服伏立康唑的用药监护过程。临床药师基于血药浓度监测,判断初始经验给药剂量的适宜性;结合患者病理生理基础,CYP2C19基因检测和合并用药调整给药剂量,确保患者用药个体化。通过及时监测和调整伏立康唑剂量,患者不良反应得以及时发现和有效预防,节约了患者药品费用,确保了患者用药安全。To evaluate clinical pharmacists participation in the personalized medicine by plasma concentration monitor and gene detection,clinical pharmacists carried out medical education before administration to the two elder patients.Estimating the suitability of the initial dosage by plasma concentration monitor.Adjusting the dosage of administration by pathophysiological basis,type of CYP2 C19 and combined drug use of two patients to insure the personalized therapy.Adverse reactions could be find in time and effective prevention.Medical expense could be saved and patients safety be insured.

关 键 词：老年急性髓系白血病 伏立康唑 治疗药物监测 基因检测 药学监护 

分 类 号：R97[医药卫生—药品]